Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 4, 2018
Previous Article Next Article

Mesoporous lipid-silica nanohybrids for folate-targeted drug-resistant ovarian cancer

Author affiliations


Folic acid (FA) targets cancer by exploiting its overexpression of folic acid receptors (FR). A novel folate conjugated lipid coated mesoporous silica nanoparticle has been synthesized in this study to enhance cellular uptake and cytotoxicity and reduce multidrug resistance (MDR) in cancer. Mesoporous silica nanoparticles (MSN) have a high loading capacity of doxorubicin (DOX) (0.012 mg mg−1) due to their high surface to volume ratio. On coating these nanoparticles (DOX:MSN) with a lipid composition of DPPC:cholesterol:DSPE-PEG2000:DSPE-PEG2000(folate) (DOX:FLMSN), a pH dependent sustained release property is achieved (∼20% to ∼97% between pH 7.4–4.5 after 168 h of drug release). The system's cellular uptake efficiency was characterized against A2780S, A2780-Cis-Res (showing FR overexpression) and PC3 cells (lacking FR overexpression). DOX:FLMSN shows significant improvement in cellular uptake in A2780S and A2780-Cis-Res but not in PC3 cells due to FR underexpression in the latter. However, in FA saturated media, the improvement is neutralized due to receptor blocking by free FA. Cytotoxicity studies confirm the enhanced cell growth inhibition of DOX:FLMSN over free DOX and DOX:LMSN in both A2780S and A2780-Cis-Res cells, thereby ameliorating MDR. Therefore, FA introduces active targeting in FR overexpressing cancer cells whilst simultaneously disrupting MDR. The nanoformulation of DOX:FLMSN can be further investigated in vivo.

Graphical abstract: Mesoporous lipid-silica nanohybrids for folate-targeted drug-resistant ovarian cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 06 Sep 2017, accepted on 10 Jan 2018 and first published on 12 Jan 2018

Article type: Paper
DOI: 10.1039/C7NJ03334F
New J. Chem., 2018,42, 2804-2814

  •   Request permissions

    Mesoporous lipid-silica nanohybrids for folate-targeted drug-resistant ovarian cancer

    S. Samanta, L. Pradhan and D. Bahadur, New J. Chem., 2018, 42, 2804
    DOI: 10.1039/C7NJ03334F

Search articles by author